3Jing ZC, Xu XQ, Han ZY, et al. Registry and survival study in Chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest, 2007, 132: 373- 379. 被引量：1
4Sitbon O,Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation, 2005,111 : 3105-3111. 被引量：1
5Badesch DB, Abman SH, Aheam GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidencebased clinical practice guidelines. Chest, 2004, 126: 35S- 62S. 被引量：1
6Barst R J, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med, 2004, 169:441-447. 被引量：1
7Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J, 2004, 25: 2243-2278. 被引量：1
8McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension : the impact of epoprostenol therapy. Circulation, 2002, 106 : 1477-1482. 被引量：1
9Melvyn R, Mclaughlin VV, from IV epoprostenol to Allen RP, et al. Transition subcutaneous treprostinil in pulmonary arterial hypertension: A controlled trial. Chest 2007,132 : 757 -763. 被引量：1
10Irene L, Miguel G, Meinhard K, et al. Efficacy of long- term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest, 2006, 129:636-1643. 被引量：1
